Norris Medicines Ltd
₹14.49
(-3.40%)
Wed, 18 Mar 2026, 09:12 pm
Health Technology
Pharmaceuticals: Major
24.5KNorris Medicines Share Price Live Chart
1 Day
0 (0%)
No Result Found
Summary
Market Cap
13.75
Net Profit
-1.24
P/B
-1.12
Sector P/E
40.12
P/E
0
EV/EBITDA
0
Debt/Equity (Industry)
0.23
Interest Cover (Industry)
9.79
ROCE (Industry)
12.90
RONW (Industry)
12.30
ROE
0
ROCE
0
Debt/Equity
0
EPS (TTM)
0
Dividend Yield
0
Book Value
-15.82
Interest Cover
-1.68
Analysis
all
- The tenure for the Norris Medicines board of directors is about average.
- Vimal's remuneration is lower than average for companies of similar size in India.
- Vimal's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Norris Medicines management team is over 5 years, this suggests they are a seasoned and experienced team.
- BSE:524414 is up 6.1% along with the Pharmaceuticals industry (6.8%) over the past month.
- Unable to evaluate Norris Medicines's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Norris Medicines's dividend against the top 25% market benchmark as the company has not reported any payouts.
- Norris Medicines's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Operating cash flow is negative therefore debt is not well covered.
- Norris Medicines has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Shareholding
| Shareholders | DEC 2025 | SEPT 2025 | JUN 2025 | MAR 2025 | DEC 2024 |
|---|---|---|---|---|---|
| Promoters | 34.00 | 34.00 | 34.00 | 34.00 | 34.00 |
| FII | 0 | 0 | 0 | 0 | 0 |
| DII | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Public | 65.93 | 65.93 | 65.93 | 65.93 | 65.93 |
| Government | 0 | 0 | 0 | 0 | 0 |
Technical Analysis
Support and Resistance
| Type | R3 | R2 | R1 | PP | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | 20.62 | 17.53 | 16.38 | 14.44 | 13.29 | 11.35 | 8.26 |
| Fibonacci | 17.53 | 16.35 | 15.62 | 14.44 | 13.26 | 12.53 | 11.35 |
| Camarilla | 16.08 | 15.80 | 15.51 | 14.44 | 14.95 | 14.66 | 14.38 |
Pivots Level: Classic
R3
+6.18
20.62
R2
+3.09
17.53
R1
+1.94
16.38
S1
-1.15
13.29
S2
-3.09
11.35
S3
-6.18
8.26
Moving Average
Period
Value
10-EMA
13.87
20-EMA
13.92
30-EMA
14.00
50-EMA
14.25
100-EMA
14.86
200-EMA
15.73
Corporate Actions
| Announcement Date | Purpose | Action | Ex Date |
|---|---|---|---|
| 14 Feb 2026 | board-meetings | Quarterly Results | |
| 14 Nov 2025 | board-meetings | Quarterly Results | |
| 01 Sept 2025 | agm | ||
| 06 Sept 2024 | agm | ||
| 29 Dec 2023 | egm | ||
| 18 Nov 2023 | agm | ||
| 09 Sept 2022 | agm | ||
| 28 Aug 2021 | agm |
Peer Comparison
No Result Found
Norris Medicines Ltd
Lupin Ltd
Torrent Pharmaceuticals Ltd
Dr Reddys Laboratories Ltd
Sun Pharmaceutical Industries Ltd
Divis Laboratories Ltd
Norris Medicines Ltd About
Norris Medicines manufactures generic pharmaceutical tablets, capsules, syrups, and suspension form products. The Company produces a range of antibiotic, anti-inflammatory, and analgesic products, as well as products for nutrition, anxiety, diabetes, and
Industry
Pharmaceuticals - Indian - Bulk Drugs & Formln
Founded
1990
Headquarters
CEO
Vimal D Shah
Employees
Contact
Website
http://www.norrispharma.com
norrismedicines@gmail.com; contact@norrispharma.co
Phone
91-2646-223462/227530
Location
Plot No 801/P & 802, GIDC Industrial Estate, Ankleshwar, Gujarat, 393002
Norris Medicines Ltd Company History
| Year | History |
|---|---|
| 2000 |
|
| 2006 |
|
| 2007 |
|
| 2012 |
|
| 2013 |
|
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800